Samarth Kulkarni Crispr Therapeutics Ag (CRSP) insider trading activity

Samarth Kulkarni is Chief Executive Officer of CRISPR Therapeutics AG. Currently has a direct ownership of 226,540 shares of CRSP, which is worth approximately $11.8 Million. The most recent transaction as insider was on Jun 01, 2018, when has been sold 15,000 shares (Common Shares) at a price of $1.81 per share, resulting in proceeds of $27,150. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 227K

1.82% 3M change

41.52% 12M change

Total Value Held $11.8 Million

Samarth Kulkarni Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 01 2018	BUY Exercise of conversion of derivative security	$27,150 $1.81 p/Share	15,000 Added 8.4%	163,560 Common Shares
Dec 21 2017	BUY Exercise of conversion of derivative security	$27,150 $1.81 p/Share	15,000 Added 9.17%	148,560 Common Shares
Dec 01 2017	BUY Grant, award, or other acquisition	$509,873 $19.12 p/Share	26,667 Added 16.64%	133,560 Restricted Stock Units
Aug 30 2017	SELL Open market or private sale	$80,000 $20.0 p/Share	4,000 Reduced 3.61%	106,893 Common Shares
Aug 28 2017	SELL Open market or private sale	$465,164 $20.09 p/Share	23,154 Reduced 17.27%	110,893 Common Shares
Apr 27 2017	SELL Open market or private sale	$37,017 $16.78 p/Share	2,206 Reduced 1.62%	134,047 Common Shares
Apr 27 2017	BUY Exercise of conversion of derivative security	$3,993 $1.81 p/Share	2,206 Added 1.59%	136,253 Common Shares
Apr 26 2017	SELL Open market or private sale	$54,823 $16.74 p/Share	3,275 Reduced 2.38%	134,047 Common Shares
Apr 26 2017	BUY Exercise of conversion of derivative security	$5,928 $1.81 p/Share	3,275 Added 2.33%	137,322 Common Shares
Apr 25 2017	SELL Open market or private sale	$86,290 $16.87 p/Share	5,115 Reduced 3.68%	134,047 Common Shares
Apr 25 2017	BUY Exercise of conversion of derivative security	$9,258 $1.81 p/Share	5,115 Added 3.55%	139,162 Common Shares
Apr 24 2017	SELL Open market or private sale	$57,610 $16.46 p/Share	3,500 Reduced 2.54%	134,047 Common Shares
Apr 24 2017	BUY Exercise of conversion of derivative security	$6,335 $1.81 p/Share	3,500 Added 2.48%	137,547 Common Shares
Apr 21 2017	SELL Open market or private sale	$51,030 $17.01 p/Share	3,000 Reduced 2.19%	134,047 Common Shares
Apr 21 2017	BUY Exercise of conversion of derivative security	$5,430 $1.81 p/Share	3,000 Added 2.14%	137,047 Common Shares
Apr 20 2017	SELL Open market or private sale	$48,608 $17.36 p/Share	2,800 Reduced 2.05%	134,047 Common Shares
Apr 20 2017	BUY Exercise of conversion of derivative security	$5,068 $1.81 p/Share	2,800 Added 2.01%	136,847 Common Shares
Apr 19 2017	SELL Open market or private sale	$130,934 $18.04 p/Share	7,258 Reduced 5.14%	134,047 Common Shares
Apr 19 2017	BUY Exercise of conversion of derivative security	$13,137 $1.81 p/Share	7,258 Added 4.89%	141,305 Common Shares

Also insider at

BDTX

Black Diamond Therapeutics, Inc. Healthcare

RPTX

Repare Therapeutics Inc. Healthcare

CNTA

Centessa Pharmaceuticals plc Healthcare

Director